Phase II clinical evaluation of the melanocortin 4 receptor agonist RM-493 for the treatment of prader-willi syndrome
Ended Project Grant Awarded Last action
- Award ID
- R01FD005094
- Recipient
-
Rhythm Pharmaceuticals, Inc. UEI G9KGU2YDQNU4
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $999,353
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Boston, MA 02116, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $210,406 | |
| Amendment | $392,688 | |
| Original award | $396,259 |
Quick answers
Who received award R01FD005094?
R01FD005094 was awarded to Rhythm Pharmaceuticals, Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on July 10, 2015.
How much is award R01FD005094 worth?
$999,353 has been obligated on R01FD005094.
Which agency awarded R01FD005094?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD005094, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award